Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 19/20 | 0.65 |
| ▸ | ABCC8 | Q09428 | 19/20 | 0.65 |
| ▸ | KCNJ11 | Q14654 | 19/20 | 0.65 |
| ▸ | KCNJ8 | Q15842 | 19/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646346 | 0.81 | ABCC9 (0.49) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL6908840 | 0.80 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL6910007 | 0.80 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL6910071 | 0.80 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL7099816 | 0.74 | ABCC9 (0.62) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6929871 | 0.74 | ABCC9 (0.62) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL6432145 | 0.73 | ABCC9 (0.76) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL7238571 | 0.71 | ABCC9 (0.45) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6930319 | 0.70 | ABCC9 (0.83) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6928353 | 0.70 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003517454-A | — | — | 2003-05-27 | — | — | JP | claimed |
| US-20020007065-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES | 2002-01-17 | — | — | US | claimed |
| EP-1075466-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2001-02-14 | — | — | EP | claimed |
| WO-2000051986-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-09-08 | — | — | WO | claimed |
| US-6518279-B2 | For treatment of asthma, epilepsy, hypertension, impotence, migraine, pain, urinary incontinence, stroke, Raynaud's syndrome, eating disorders, functional bowel disorders, and neurodegeneration; inotropic agents | ABBOTT LABORATORIES | 2003-02-11 | — | — | US | disclosed |
| US-20020007065-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES | 2002-01-17 | — | — | US | disclosed |
| EP-1075466-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-2000051986-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007065-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | KCNN1, KCNJ2, KCNH1 | ABCC9 416/4885ABCC8 743/4885KCNJ11 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.